Sandoz’s Tyruko biosimilar granted FDA approval to treat relapsing MS
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Read More
Tag: Tyruko
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
